Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data Nature.com Nawigacja wpisu Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome – Business Wire FDA issues first guidance on AI in medicine development – pharmaphorum
